TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22181693

Group type: EXPERIMENTAL
Intervention: Topical Terbinafine Nail Solution (TNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amorolfine 5% nail lacquer
Number of subjects: 0
Study: 21212216

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 132
Study: 20002088

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Warfarin (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cocktail of all five drugs
Number of subjects: 30
Study: 17155989

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Sildenafil to Tadalafil
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Tadalafil to Sildenafil
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Treatment Preference
Number of subjects: 2425
Study: 15198743

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 7
Study: 12171082

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 9696971

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Subtotal thyroidectomy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Completion thyroidectomy
Number of subjects: 141
Study: 10155594

Group type: EXPERIMENTAL
Intervention: Lenograstim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no lenograstim)
Number of subjects: 0
Study: 2502251

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing L-alanine and glucose
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard glucose based oral rehydration solution
Number of subjects: 97
Study: 1012910

Group type: EXPERIMENTAL
Intervention: Feedback intermittency with random wave pattern of 9.76 cpm and magnitudes of 0.0, 0.2, 0.4, 0.6, 0.8, 1.0, and 1.5 sec.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30551161

Group type: EXPERIMENTAL
Intervention: Renal relapse(s)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Baseline renal function
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Long-term monitoring (3-monthly urinalysis)
Number of subjects: 535
Study: 27155825

Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar inter-body fusion (TLIF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterolateral instrumented lumbar fusion (PLF)
Number of subjects: 100
Study: 26347545

Group type: EXPERIMENTAL
Intervention: Extubation at 60°
Number of subjects: 46

Group type: COMPARATOR
Intervention: Extubation at 90°
Number of subjects: 46
Study: 23596809

Group type: EXPERIMENTAL
Intervention: Xiaoaiping Injection (XAP) plus best supportive treatment (BST)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Best supportive treatment (BST)
Number of subjects: 68
Study: 22005564

Group type: EXPERIMENTAL
Intervention: Western therapy + Modified Liang‐Ge San (group L)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Western therapy only (group X)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patients with sepsis
Number of subjects: 64
Study: 19835310

Group type: EXPERIMENTAL
Intervention: Navigation-assisted gap technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Anatomic bony landmark method
Number of subjects: 46
Study: 16915119

Group type: EXPERIMENTAL
Intervention: Intra-arterial reteplase (0.5, 1, 1.5, and 2 units) and intravenous abciximab (0.25 mg/kg bolus followed by 0.125 mg/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intra-arterial reteplase and intravenous abciximab
Number of subjects: 20
Study: 14669038

Group type: EXPERIMENTAL
Intervention: i.m. corticosteroid injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: immobilisation in a wrist splint
Number of subjects: 30
Study: 10945548

Group type: EXPERIMENTAL
Intervention: Freehand System (neuroprosthesis)
Number of subjects: 6
Study: 9299255

Group type: EXPERIMENTAL
Intervention: High-fiber diet plan
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 35
Study: 8298669

Group type: EXPERIMENTAL
Intervention: Balneotherapy (mud baths or mud packs, mineral baths, electrotherapies, and gynecological exercises)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no balneotherapy)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 57
Study: 3115049

Group type: EXPERIMENTAL
Intervention: Radiant heat supply group (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study: 30303421

Group type: EXPERIMENTAL
Intervention: Whole body heat stress (WBHS) for up to 30 minutes at 73 °C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole body heat stress (WBHS)
Number of subjects: 30
Study: 26975205

Group type: EXPERIMENTAL
Intervention: Geriatric Interdisciplinary Home Rehabilitation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Conventional geriatric care and rehabilitation
Number of subjects: 205
Study: 23946326

Group type: EXPERIMENTAL
Intervention: varenicline (1mg, twice per day for 12 weeks)
Number of subjects: 237

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 237
Study: 22498504

Group type: EXPERIMENTAL
Intervention: Preservative-free levocabastine 0.05% ophthalmic solution
Number of subjects: 92

Group type: COMPARATOR
Intervention: Preserved levocabastine 0.05% ophthalmic suspension
Number of subjects: 92
Study: 20441832

Group type: EXPERIMENTAL
Intervention: Anti-slip devices
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Control Group (not using anti-slip devices)
Number of subjects: 25000
Study: 17717030

Group type: EXPERIMENTAL
Intervention: Cinacalcet (25 mg/day titrated up to 100 mg/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 144
Study: 15854116

Group type: EXPERIMENTAL
Intervention: Fissure sealants with glass ionomer
Number of subjects: 508

Group type: COMPARATOR
Intervention: Standard package of dental health education
Number of subjects: 508
Study: 12535831

Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 11008927

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplements for 1 year
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low erythrocyte magnesium levels (< 2.3 mmol/L)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 23
Study: 8860762

Group type: EXPERIMENTAL
Intervention: Vocal cord stripping (S)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 34
Study: 1515974

Group type: EXPERIMENTAL
Intervention: Sandostatin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 41
Study: 6313557

Group type: EXPERIMENTAL
Intervention: Group I: local tumor irradiation (approximately 4,000 cGy) combined with 'one-time' irradiation of the upper and lower half of the body, midplane dose averaging 880 cGy.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group II: two half-body irradiation treatments through anterior-posterior fields, average dose of 800 cGy given in two fractions (600 and 200 cGy).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All patients (Group I and II) received X-ray films showing complete regression of the primary tumor.
Number of subjects: 42
Study: 30449838

Group type: EXPERIMENTAL
Intervention: Randomized phase II trial designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 25832306

Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (comparison between groups)
Number of subjects: 26
Study: 25085073

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (L.GG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22483481

Group type: EXPERIMENTAL
Intervention: Early ureteric stent removal (8 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine ureteric stent removal (15 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Presence of UTI
Number of subjects: 90
Study: 20055782

Group type: EXPERIMENTAL
Intervention: Erdosteine (5-8 mg/kg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 18807725

Group type: EXPERIMENTAL
Intervention: Bee-venom therapy combined with Methotrexate, Sulfasalazine, and Meloxicam (3 months treatment)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medication group (Methotrexate, Sulfasalazine, Meloxicam)
Number of subjects: 100
Study: 15691219

Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 12511152

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10797151

Group type: EXPERIMENTAL
Intervention: CWS to 60% of vital capacity
Number of subjects: 12

Group type: COMPARATOR
Intervention: DS of 600 ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CWS + DS
Number of subjects: 12
Study: 8656557

Group type: EXPERIMENTAL
Intervention: Granisetron (GRN) and Dexamethasone (DEX) on day 1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Granisetron (GRN) alone
Number of subjects: 40
Study: 1797463

Group type: EXPERIMENTAL
Intervention: Gyne T* 380 Slimline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gyne T* 380
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both devices (Gyne T* 380 Slimline and Gyne T* 380)
Number of subjects: 100
Study: 6137970

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypnomidate
Number of subjects: 20
Study: 31544488

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 60
Study: 31359463

Group type: EXPERIMENTAL
Intervention: Locally fitted models of diameter-height (D:H) relationships
Number of subjects: 42627

Group type: COMPARATOR
Intervention: Generic models (parameterized national, georegional, and pantropical equations)
Number of subjects: 42627
Study: 28252842

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC) implantation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMC)
Number of subjects: 88
Study: 27648618

Group type: EXPERIMENTAL
Intervention: Mechanical stapler
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monofilament sutures
Number of subjects: 120
Study: 24658550

Group type: EXPERIMENTAL
Intervention: VAMUF
Number of subjects: 60

Group type: COMPARATOR
Intervention: AVMUF
Number of subjects: 60
Study: 22954459

Group type: EXPERIMENTAL
Intervention: Extended Internet intervention (Alcohol Help Center [AHC])
Number of subjects: 170

Group type: COMPARATOR
Intervention: Brief Internet intervention (Check Your Drinking [CYD] screener])
Number of subjects: 170
Study: 19284179

Group type: EXPERIMENTAL
Intervention: 800 mg of valerian
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 17463353

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy enhanced with focused complicated grief components
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard interpersonal psychotherapy
Number of subjects: 19
Study: 11156086

Group type: EXPERIMENTAL
Intervention: Thoracoscopic, internal intercostal nerve block with 3 cc of 0.5% bupivacain at T2, T3, and T4 intercostal levels
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bilateral thoracic sympathectomy without the block
Number of subjects: 32
Study: 9362354

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU initially, followed by 5 x 10(5) KIU/h infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 80
Study: 1412680

Group type: EXPERIMENTAL
Intervention: Test plastic (non-DEHP plastic bag)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control plastic (DEHP plastic bag)
Number of subjects: 2
Study: 3990734

Group type: EXPERIMENTAL
Intervention: Strenuous exercise with weight-loss
Number of subjects: 28

Group type: COMPARATOR
Intervention: Strenuous exercise with weight-maintenance
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-study follow-up
Number of subjects: 28
Study: 29238988

Group type: EXPERIMENTAL
Intervention: Plerixafor plus granulocyte-colony-stimulating factor
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo plus granulocyte-colony-stimulating factor
Number of subjects: 101
Study: 26395778

Group type: EXPERIMENTAL
Intervention: Reversed gap (RG) technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical gap (GT) technique
Number of subjects: 60
Study: 24626142

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19
Study: 22271753

Group type: EXPERIMENTAL
Intervention: 24 weeks of exercise training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study: 20207331

Group type: EXPERIMENTAL
Intervention: Discography with pain scores
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biochemical analysis of disc lavage fluid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MRI scoring for Pfirrmann grading of the lumbar discs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (3 scoliosis patients without back pain)
Number of subjects: 24
Study: 19143194

Group type: EXPERIMENTAL
Intervention: Amlodipine (normodipine) administered as monotherapy for 12 weeks
Number of subjects: 52
Study: 15814391

Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol (50 microg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Transcervical Foley catheters (Size 16F, 30 ml balloon)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Transcervical Foley catheters
Number of subjects: 96
Study: 12414433

Group type: EXPERIMENTAL
Intervention: Preoperative photoreceptor displacement
Number of subjects: 20

Group type: COMPARATOR
Intervention: No preoperative photoreceptor displacement
Number of subjects: 20
Study: 10492406

Group type: EXPERIMENTAL
Intervention: Ropivacaine (8.0 ml of 1.0% ropivacaine with 50 IU/ml hyaluronidase)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine (8.0 ml of 0.75% bupivacaine with 50 IU/ml hyaluronidase)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 80
Study: 8611064

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonalcoholic placebo
Number of subjects: 0
Study: 1706910

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (84 micrograms administered in each nostril twice a day for 7 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (administered in each nostril twice a day for 7 days)
Number of subjects: 13
Study: 31152545

Group type: EXPERIMENTAL
Intervention: Aronia whole fruit powder (12 mg, 10 g berries)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aronia extract powder (116 mg, 75 g berries)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aronia extract (day 1 consumption)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aronia extract (12 weeks later)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aronia extract
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aronia whole fruit
Number of subjects: 66
Study: 26431983

Group type: EXPERIMENTAL
Intervention: ID 15 μg HA
Number of subjects: 600

Group type: COMPARATOR
Intervention: ID 6 μg HA
Number of subjects: 600

Group type: COMPARATOR
Intervention: ID 9 μg HA
Number of subjects: 600

Group type: COMPARATOR
Intervention: SC 15 μg HA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: ID 15 μg HA (single or two doses)
Number of subjects: 600

Group type: COMPARATOR
Intervention: SC vaccine
Number of subjects: 600
Study: 23537722

Group type: EXPERIMENTAL
Intervention: recombinant single‐chain factor VIII (rVIII‐SingleChain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa‐FP)
Number of subjects: 0
Study: 21115083

Group type: EXPERIMENTAL
Intervention: Diet Change (DC) - Nutrient-dense Mediterranean diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: No Change (NC) - Control group
Number of subjects: 25
Study: 21536989

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17389293

Group type: EXPERIMENTAL
Intervention: Web-based proactive system (PRECARES) with 2 monthly letters and follow-up calls
Number of subjects: 6665

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6665

Group type: EXPERIMENTAL
Intervention: US mail reminder for employee subgroup
Number of subjects: 6665

Group type: EXPERIMENTAL
Intervention: E-mail reminder for employee subgroup
Number of subjects: 6665

Group type: COMPARATOR
Intervention: Control group for employee subgroup
Number of subjects: 6665
Study: 16118910

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 26
Study: 11865836

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF; 400 mg, 3 times daily)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 10529021

Group type: COMPARATOR
Intervention: Hydromorphone (HYD) 0 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 4 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 8 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) 16 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 14
Study: 7773850

Group type: EXPERIMENTAL
Intervention: Antifungal denture soaking solution (48 mL nystatin liquid, 100,000 IU/mL, dissolved in 432 mL of distilled water producing 10,000 IU nystatin/mL solution) used as an adjunct to nystatin vaginal lozenge (100,000 IU/g, dissolved in the mouth three times daily for seven days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antifungal denture soaking solution
Number of subjects: 0
Study: 1691385

Group type: EXPERIMENTAL
Intervention: Felodipine-ER 5 mg once daily (n = 49)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 101
Study: 6248087

Group type: EXPERIMENTAL
Intervention: Pipecurium bromide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pancuronium bromide
Number of subjects: 90
Study: 29986613

Group type: EXPERIMENTAL
Intervention: Intermittent oxytocin infusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continued oxytocin infusion
Number of subjects: 200
Study: 31083052

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) plus enhanced usual care
Number of subjects: 94

Group type: COMPARATOR
Intervention: Enhanced usual care (UC) alone
Number of subjects: 94
Study: 27943450

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 26222998

Group type: EXPERIMENTAL
Intervention: Weight-stigmatizing video
Number of subjects: 72

Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 72
Study: 23457220

Group type: EXPERIMENTAL
Intervention: SpO2 target range 80‐92%
Number of subjects: 16

Group type: COMPARATOR
Intervention: SpO2 target range 85‐96%
Number of subjects: 16
Study: 20817750

Group type: EXPERIMENTAL
Intervention: Personalized imagery induction (stress)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Personalized imagery induction (neutral)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 37
Study: 19298496

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 16421131

Group type: EXPERIMENTAL
Intervention: Active monitoring (n = 69, simple tablet count and electronic monitoring)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (n = 43, no monitoring)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self report
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Simple tablet count
Number of subjects: 112
Study: 14738230

Group type: EXPERIMENTAL
Intervention: Theophylline (2x250 mg x day(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetazolamide (2x250 mg x day(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11389294

Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture (Heliox)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Racemic epinephrine (RE)
Number of subjects: 29
Study: 8996307

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (1 mg/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8097802

Group type: EXPERIMENTAL
Intervention: oral captopril (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (n = 8)
Number of subjects: 16
Study: 3316564

Group type: EXPERIMENTAL
Intervention: Gentamicin and ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study: 31520460

Group type: EXPERIMENTAL
Intervention: Coblopasvir (30 or 60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Coblopasvir (60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks (for patients with cirrhosis)
Number of subjects: 110